Abstract: Azabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is a group of formula (a), (b) or (c): ##STR2## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.10 alkyl, aralkyl or di(C.sub.1 -C.sub.4) alkylamino(C.sub.1 -C.sub.6)alkyl;R.sub.2, R.sub.3 and R.sub.4 may be the same or different and each is hydrogen, amino, halogen, C.sub.1 -C.sub.4 alkoxy or phthalimide; X is O or NH;R is C.sub.1 -C.sub.4 alkyl; andY is NR, O or S;having 5-HT.sub.3 receptor antagonist activity.

Abstract: A pharmaceutical oil-in-water type microemulsion having an action of potentiating the activities of anti-cancer agents, said micro-emulsion comprisesfine particles of a vegetable oil or a triglyceride of a medium-chain fatty acid having 8 to 12 carbon atoms containing 0.1 to 10% (w/v) of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine malate of formula (I) below, ##STR1## an aqueous medium, and 0.05 to 25% (w/v) of a physiologically acceptable phospholipid for dispersing said fine particles in said aqueous medium.

Abstract: 1-Hydroxyvitamin D derivatives which are esters of 1-hydroxyvitamin D with vitamin A acid. They are useful for an agent for preventing and treating osteoporosis, cutaneous ulcer and tumor.

Abstract: Stabilized fat-soluble vitamin compositions are disclosed which comprise fat-soluble vitamins and carotenoids as a stabilizer. They are stable to light and have a wide range of applications such as medicines, veterinary medicines, food additives, feed additives, nutrient supplements or the like.

Abstract: A sustained release composition containing a chemical substance in a matrix. The matrix substantially comprises a hemicellulose extracted from wheat bran under alkaline conditions or a wheat bran extract containing the hemicellulose. The chemical substance is released at a controlled rate from the composition over a long period of time.

Abstract: There is disclosed a pharmaceutical composition for animals comprising at least one of a vinegar, a flesh of Japanese apricot, oranges, tomatoes and strawberries; and saccharides or a combination of saccharides and an edible organic acid, and optionally containing Lactobacillus bifidus.

Abstract: (24S)- and (24R)-1.alpha.,25-Dihydroxyvitamin D.sub.4 compounds and processes for preparing same. Ergosta-5,7-diene compounds which are useful intermediates in the synthesis of the 1.alpha.,25-dihydroxyvitamin D.sub.4 compounds. The D.sub.4 compounds are expected to possess an interesting pharmacological activity in association with the active-type vitamins D.sub.3 and D.sub.2.

Abstract: Glycerides of eicosapentaenoic acid (EPA) and other higher fatty acids, which contain high levels of EPA and docosahexaenoic acid. These glycerides are incorporated in oils and fats products such as margarine, shortening, mayonnaise, butter, dressing or edible oil.

Abstract: Frozen instant cooking noodles having a cross-sectional void space percent of 40 to 80% which are capable of uniformly thawing by heat in a very short time to provide a fully cooked noodles having good texture for eating are produced by subjecting noodles to .alpha. conversion so as to control a yield of the noodles within the range of 200 to 280%, quickly cooling the .alpha. converted noodles in cold water at 0.degree. to 5.degree. C., arranging individual strings of the noodle at random to form a noodle lump and freezing the lump.

Abstract: Vitronectin produces very high therapeutic effects upon injuries of the corneal epithelium. When applied to lesions of the corneal epithelium in the form of eye drops, Vitronectin induces rapid cure of the lesions with regeneration of normal cells. Moreover Vitronectin can be sterilized by autoclaving.

Abstract: 1-Phenoxycarbonyl-2-pyrrolidinone derivatives of formula (I) or (I') are disclosed. ##STR1## wherein R is a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, a nitro group or a halogen atom and n is 1 or 2, and R' is the same as R, but including further a hydrogen atom. The compounds of formula (I') are useful as nootropic agents.

Abstract: There is disclosed a wheat flour comprising not less than 60% by weight of flours which pass through a screening surface having an opening of 75 microns and remain on a screening surface having an opening of 38 microns, which is suitable for the manufacture of a bread, a pasta and noodle. Also disclosed is a wheat flour composite for breadstuff wherein the wheat flour is compounded with a thicker and optionally a malt. The wheat flour composite is suitable for the manufacture of a high quality bread having good appearance, good textural and taste characteristics.

Abstract: Disclosed are compounds of formula I ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, benzyl or an indolyl carbonyl group, R.sub.2 is a saturated or unsaturated 5- or 8-membered heterocyclic group containing as a hetero atom one or more nitrogen atoms, the heterocyclic group is optionally substituted at an N or C atom by a C.sub.1 -C.sub.6 alkyl or aralkyl group, n is an integer of 1 to 5 and one or more hydrogen atoms, in an alkylene chain --(CH.sub.2).sub.n -- are optionally substituted by a C.sub.1 -C.sub.6 alkyl, phenyl and/or hydroxyl group, physiologically acceptable salts and quaternary ammonium salts thereof. The compounds are selective antagonists of 5-HT.sub.3 receptors and are useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

Abstract: The plasmid of the present invention contains Leu 2 gene (.beta.-isopropylmaleate dehydrogenase gene) from Saccharomycopsis lipolytica and an autonomously replicating sequence (hereafter referred to as ARS) and can be a shuttle vector between Escherichia coli and Saccharomycopsis lipolytica since it is produced from shuttle vector pVC 1 of Escherichia coli and Saccharomyces cerevisiae. An exogenous useful gene is inserted into the plasmid of the present invention, namely, shuttle vector to transform Escherichia coli, whereby a large quantity of plasmids are obtained. It becomes possible to produce a useful substance in Saccharomycopsis lipolytica as a host using the plasmid.

Abstract: Disclosed is a rhodanine derivative of formula (I).A rhodanine derivative of formula (I) ##STR1## wherein R.sup.1 is hdyrogen, C.sub.1 -C.sub.8 alkyl, carboxyl(C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxycarbonyl(C.sub.1 -C.sub.4)alkyl;R.sup.2 is --CH.sub.2 --CH.sub.2 --R.sup.3, CH.dbd.CH.sub.m R.sup.3 (m is 0 or 1), ##STR2## (R is C.sub.1 -C.sub.3 alkyl) or --CH.sub.2n CONHR.sup.4 (n is 0 or 1-4); R.sup.3 is a thienyl or furyl group which may be substituted by C.sub.1 -C.sub.3 alkyl or halogen; a pyrrolyl group which may be substituted by carboxy(C.sub.1 -C.sub.3)alkyl on the nitrogen atom; or a phenyl group which may be substituted by one or more substituents selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxyl, halogen, trifluoromethyl, carboxyl, (C.sub.1 -C.sub.3)alkoxycarbonyl, cyano, carboxy(C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.6)alkoxycarbonyl(C.sub.1 -C.sub.3)alkoxy, benzyloxycarbonyl(C.sub.1 -C.sub.3)alkoxy, piperidinylcarbonyl(C.sub.1 -C.sub.

Abstract: Pyrrolidine derivatives of formula (I) are disclosed. ##STR1## wherein the ring A represents the following heterocyclic ring ##STR2## The compounds of formula (I) are useful as nootropic agents.

Abstract: A dieting agent is disclosed which comprises an aqueous solution or a solid substance of a concentration .alpha.-amylase inhibiting substance which is produced by a process which comprises heat treating a supernatant fraction of an aqueous extract of wheat or wheat flour to modify unnecessary protein contaminants in the supernatant fraction, removing a modified protein from said fraction, subjecting a resulting aqueous solution containing an .alpha.-amylase inhibiting substance to a concentration treatment using an ultrafiltration membrane to form an aqueous solution of a concentrated .alpha.-amylase inhibiting substance or drying the aqueous solution. The dieting agent exhibits a body weight gain-inhibiting effect.

Abstract: (22E)-5,7,22-Ergostatriene-1.alpha.,3.beta.,25-triol and the 24-epimer thereof which are new intermediates for the synthesis of 1.alpha.,25-dihydroxyvitamin D.sub.2 and the 24-epimer thereof. A new process for the preparation of 1.alpha.,25-dihydroxyvitamin D.sub.2 and the 24-epimer thereof is also described which comprises irradiation of (22E)-5,7,22-ergostatriene-1.alpha.,3.beta.,25-triol or the 24-epimer thereof followed by isomerization.

Abstract: A process of preparing an .alpha.-amylase inhibiting substance from wheat is disclosed which comprises heat treating a supernatant fraction of an aqueous extract of wheat or wheat flour to modify unnecessary protein contaminants in the supernatant fraction, removing a modified protein from said fraction, and subjecting a resulting aqueous solution containing an .alpha.-amylase inhibiting substance to a concentration treatment using an ultrafiltration membrane. As the ultrafiltration membrane is used the membrane of polyacrylonitrile, polyolefin, polysulfone, polyimide or polypropylene materials, each having a fractionation molecular weight of 5,000, 6,000, 8,000, 10,000, 13,000, 20,000, 30,000, 50,000, 100,000 and 200,000 Dalton cut off.

Abstract: Pharmaceutical preparations for oral administration are disclosed which comprise (a) an acidic non-steroidal anti-inflammatory agent having the mean particle size of about 100 .mu.m or less and (b) a protein hydrolyzate or a polypeptide having the mean molecular weight of 4000-12000. The pharmaceutical preparations are in the form of tablets, granules, capsules and dry syrups. They achieve high bioavailability of the anti-inflammatory agent, e.g., ibuprofen.